Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia

Figures & data

Table 1 Baseline demographic and laboratory data of the studied patients

Variables	N=300
Age (years)	44.35±9.97
Sex
Male	82 (63.08%)
Female	48 (36.92%)
Hb (g/dL)	12.39±1.01
WBC (×10^3)/mm^3	3.92±1.01
Platelet (×10^3)/mm^3	28.06±9.48
ALT (IU/L)	47.87±16.74
AST (IU/L)	47.12±14.45
Serum bilirubin (mg/dL)	1.55±0.51
Serum albumin (mg/dL)	3.81±0.42
INR	1.33±0.22
PCR (×10^5 copies/mL)	9.81±17.36
Liver status
Non-cirrhotic	38 (29.23%)
Cirrhotic	92 (70.77%)
Child–Pugh score (N=97)
Child A	75 (81.52%)
Child B	17 (18.48%)
Status of spleen
Splenectomy	13 (10%)
Huge splenomegaly	18 (13.85%)
Non-huge spleen	99 (76.15%)
Bone marrow examination
Normal	110 (84.62%)
Megakaryocyte hypoplasia or aplasia	20 (15.38%)
Treatment response
Responders	111 (85.38%)
Nonresponders	19 (14.62%)

Note: Data are presented as mean ± SD or number and percentage.

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; Hb, hemoglobin; INR, international normalized ratio; WBC, white blood cells.

Table 2 Incidence of side effects during the treatment period in the studied patients

	N=130
Absence of side effects	102 (78.46%)
Presence of side effects	28 (21.54%)
Mild elevated liver enzymes	13 (10%)
Headache	10 (7.69%)
Fatigue	7 (5.38%)
Dry mouth	2 (1.54%)

Table 3 Predictors of nonresponse to therapy in the studied patients (univariate analysis)

Variables	Responders, N=111	Nonresponders, N=19	P-value
Age (years)	44.18±9.75	45.32±11.39	0.6861
Sex
Male	69 (62.16%)	13 (68.42%)	0.7909
Female	42 (37.38%)	6 (31.58%)
Hb (g/dL)	12.4±1.02	12.35±0.97	0.8553
WBC (×10^3)/mm^3	3.92±1.03	3.96±0.92	0.845
Platelet (×10^3)/mm^3	27.76±9.26	29.84±10.75	0.4343
ALT (IU/L)	48.43±15.22	44.58±24.11	0.5079
AST (IU/L)	46.74±14.29	49.32±15.55	0.5062
Serum bilirubin (mg/dL)	1.51±0.49	1.76±0.57	0.0825
Serum albumin (mg/dL)	3.84±0.42	3.66±0.54	0.1874
INR	1.32±0.23	1.36±0.19	0.5004
PCR (×10^5 copies/mL)	9.99±18.27	8.75±10.82	0.6838
Liver status
Non-cirrhotic	34 (30.63%)	4 (21.05%)	0.3963
Cirrhotic	77 (69.37%)	15 (78.95%)
Child–Pugh score
Child A	65 (84.42%)	10 (66.67%)	0.1052
Child B	12 (15.58%)	5 (33.33%)
Splenectomy
Yes	6 (5.41%)	7 (36.84%)	0.0001
No	105 (94.59%)	12 (63.16%)
Splenomegaly degree
Huge	11 (10.84%)	7 (58.33%)	<0.0001
Non-huge	94 (89.52%)	5 (41.67%)
Bone marrow status
Normal	8 (7.21%)	12 (63.16%)	<0.0001
Megakaryocyte hypoplasia or aplasia	103 (92.76%)	7 (36.84%)

Nots: Data are presented as mean ± SD or number and percentage. Significant values are shown in bold.

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; Hb, hemoglobin; INR, international normalized ratio; WBC, white blood cells.

Table 4 Multivariate analysis of predictors of nonresponse to eltrombopag in the studied patients

	OR (95% CI)	P-value
Splenectomy	0.065 (0.018–0.233)	0.001
Splenomegaly degree	0.754 (0.235–1.652)	0.123
Bone marrow status	0.145 (0.014–0.347)	0.001

Note: Significant values are shown in bold.